ResultsIQ

ResultsIQ › Latest results › Windlas Biotech Limited

Windlas Biotech Limited Q1 FY27 results deck summary

NSE: WINDLAS · BSE: 543329

Results deck of 10 Aug 2026, summarised by AI from the filing.

Windlas Biotech reported highest-ever quarterly revenue of ₹248 cr in Q1FY27, up 18% YoY, with Plant-6 commercialization on track in H1 FY27.

Key takeaways

  1. Guidance Commercialization of Plant-6 on track in H1 FY27 to strengthen manufacturing capacity.
  2. Buyback Completed ₹47 cr buyback in Q1FY27 without promoter participation, and declared FY26 dividend of ₹13 cr.
  3. CDMO growth Generic Formulations CDMO revenue grew 29% YoY to ₹207 cr, driven by customer expansion and new product launches.

Original filing on BSE

Windlas Biotech Limited Q1 FY27 results

As filed: Revenue ₹248 cr (+18% year on year), EBITDA ₹26.7 cr (+3% year on year), PAT ₹17.7 cr (−2% year on year), EBITDA margin 10.8% (−162 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹239 cr (+17% year on year), EBITDA ₹25.3 cr (+1% year on year), PAT ₹16.0 cr (0% year on year), EBITDA margin 10.6% (−171 bps). Score 33 of 100, Below trend. Revenue and profit growth were below the company's own trend; EBITDA growth was well below it. EBITDA margin fell 171 bps year on year. Revenue rose ₹35.5 cr on a year ago, more than the ₹32.0 cr it added the year before. Share price after the results: +4.3% in 29 days (Nifty 500: +2.4%).
  • Q3 FY26: Revenue ₹233 cr (+20% year on year), EBITDA ₹24.4 cr (+2% year on year), PAT ₹15.0 cr (−6% year on year), EBITDA margin 10.5% (−185 bps). Score 31 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 185 bps year on year. Profit fell 17% from last quarter. Revenue rose ₹38.1 cr on a year ago, more than the ₹33.0 cr it added the year before. Share price after the results: −11.2% in 29 days (Nifty 500: −4.0%).
  • Q2 FY26: Revenue ₹222 cr (+19% year on year), EBITDA ₹29.0 cr (+26% year on year), PAT ₹18.0 cr (+13% year on year), EBITDA margin 13.1% (+76 bps). Score 54 of 100, In line with trend. Revenue and profit growth were below the company's own trend; EBITDA growth was in line with it. EBITDA margin rose 76 bps year on year. Revenue rose ₹35.0 cr on a year ago, more than the ₹34.0 cr it added the year before. Share price after the results: −16.6% in 29 days (Nifty 500: +1.4%).
  • Q1 FY26: Revenue ₹210 cr (+20% year on year), EBITDA ₹26.0 cr (+30% year on year), PAT ₹18.0 cr (+38% year on year), EBITDA margin 12.4% (+95 bps). Score 64 of 100, In line with trend. Revenue growth was below the company's own trend; EBITDA growth was in line with it; profit growth was above it. EBITDA margin rose 95 bps year on year. Revenue rose ₹35.0 cr on a year ago, more than the ₹30.0 cr it added the year before. Share price after the results: +5.9% in 30 days (Nifty 500: +2.1%).
  • Q4 FY25: Revenue ₹203 cr (+19% year on year), EBITDA ₹25.0 cr (+9% year on year), PAT ₹16.0 cr (−6% year on year), EBITDA margin 12.3% (−114 bps). Score 32 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 114 bps year on year. Revenue rose ₹32.0 cr on a year ago, more than the ₹30.0 cr it added the year before. Share price after the results: −8.9% in 29 days (Nifty 500: +2.0%).
  • Q3 FY25: Revenue ₹195 cr (+20% year on year), EBITDA ₹24.0 cr (+20% year on year), PAT ₹16.0 cr (+7% year on year), EBITDA margin 12.3% (−4 bps). Score 34 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA and profit growth were well below it. EBITDA margin was flat year on year. Revenue rose ₹33.0 cr on a year ago, against ₹42.0 cr the year before.
  • Q2 FY25: Revenue ₹187 cr (+22% year on year), EBITDA ₹23.0 cr (+28% year on year), PAT ₹16.0 cr (+14% year on year), EBITDA margin 12.3% (+53 bps). Score 66 of 100, Above trend. EBITDA margin rose 53 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Windlas Biotech Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.